Daily times four vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A phase II trial of a novel schedule
| Autor: | V. A. Rhodes, C. H. Spiridonidis, L. R. Laufman, J. Jones |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Phases of clinical research Filgrastim Neutropenia Vinblastine Vinorelbine Severity of Illness Index Gastroenterology Disease-Free Survival Drug Administration Schedule Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Confidence Intervals medicine Humans Infusions Intravenous Survival rate Aged Neoplasm Staging Chemotherapy Performance status business.industry Hematology Middle Aged Prognosis medicine.disease Surgery Survival Rate Treatment Outcome Oncology Female Cisplatin business Febrile neutropenia medicine.drug |
| Zdroj: | Annals of Oncology. 10:989-991 |
| ISSN: | 0923-7534 |
| Popis: | Summary Purpose To evaluate the efficacy of a novel multiday schedule of vinorelbine and cisplatin in patients with advanced NSCLC. Patients and methods Thirty patients were enrolled, including 27 patients with stage IV disease, and 11 patients with performance status of 2. They received a maximum of four chemotherapy cycles with cisplatin 20 mg/m2/day and vinorelbine 15 mg/m2/day intravenously (i.v.) for four consecutive days, every three weeks, with prophylactic filgrastim. Results Sixteen patients responded (53%, 95% confidence interval (95% CI): 34%–72%), including two complete and fourteen partial confirmed responses. Median survival for all patients was 8.1 months, with actuarial one-year and two-year survival rates of 40% and 15%. Despite prophylactic filgrastim, the delivered vinorelbine dose intensity of 16.8 mg/m2/week caused febrile neutropenia in 48% of patients (16% of cycles), resulting in one treatment-related death. Common nonhematologic toxicities included delayed emesis, asthenia, and constipation. Conclusions This multiday vinorelbine-cisplatin schedule is highly active against advanced NSCLC but results in frequent neutropenic complications. The myelotoxicity and antitumor efficacy of vinorelbine in NSCLC patients may be schedule-dependent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|